Core Points - The announcement details a change in shareholder equity for Shanghai Medicy Bio-Pharmaceutical Co., Ltd, specifically a reduction in shareholding by major shareholder Lin Changqing [1][2] - Lin Changqing has reduced his shareholding from 5,473,654 shares (4.07%) to 4,523,654 shares (3.37%), resulting in a total reduction of 950,000 shares (0.71%) [1][2] - The combined shareholding of Lin Changqing and his associate Chen Guoxing decreased from 10,348,808 shares (7.70%) to 9,398,808 shares (7.00%) [1][2] Shareholder Information - Lin Changqing is the primary shareholder involved in the equity change, while Chen Guoxing remains unchanged with 487,515.4 shares (3.63%) [2] - The equity change does not trigger mandatory tender offer obligations and will not affect the company's controlling shareholder or actual controller [2] Additional Notes - The equity change is part of a previously disclosed share reduction plan, which is still in progress as of the announcement date [2] - The company will continue to comply with relevant regulations and fulfill its information disclosure obligations [2][3]

Core Viewpoint - Medisi (688202.SH) announced a legal dispute involving its wholly-owned subsidiary Medisi Puya, with a lawsuit amounting to approximately 159 million yuan filed by Hongxu Biopharmaceutical Technology [2][10] Group 1: Legal Dispute Details - The lawsuit is based on a technical service contract signed on December 18, 2020, where Medisi Puya was contracted to conduct non-clinical safety evaluations for Hongxu Biopharmaceutical's Class I biopharmaceuticals [8][9] - Hongxu Biopharmaceutical claims that Medisi Puya breached the contract and is seeking to terminate the contract, along with compensation for losses totaling approximately 1.5 billion yuan [9] - The total amount involved in the lawsuit is approximately 159 million yuan, which includes various claims such as breach of contract penalties and return of service fees [9] Group 2: Company Financial Performance - In the first half of 2025, Medisi reported revenue of approximately 540 million yuan, a year-on-year increase of 3.64% [5][6] - The net loss attributable to shareholders was approximately 12.9 million yuan, a reduction of 57.3 million yuan compared to the same period last year, primarily due to increased revenue and controlled costs [5][6] - The company’s total assets as of the end of the reporting period were approximately 2.83 billion yuan, with net assets of approximately 2.08 billion yuan [6] Group 3: Company Response to the Lawsuit - Medisi stated that it does not recognize the claims made by Hongxu Biopharmaceutical and will actively respond to the lawsuit, including potential counterclaims [10] - The company believes it has fulfilled its contractual obligations and that the project has received clinical trial approval from the National Medical Products Administration (NMPA) [10] - Medisi expects that the lawsuit will not have a significant impact on its daily operations and will continue to maintain stable business development [10]

9月4日晚间，美迪西（688202.SH，股价64.38元，市值86.50亿元）公告称，其全资子公司美迪西普亚医药科技（上海）有限公司（以下简称"美迪西普亚"） 作为被告，卷入一起技术服务合同纠纷案件。截至目前，该案件已立案，尚未开庭审理。 公告显示，该技术服务合同纠纷案的原告方为鸿绪生物医药科技（北京）有限公司（以下简称"鸿绪生物"），涉及诉讼金额约1.59亿元。 美迪西表示，诉讼金额仅为鸿绪生物单方提起诉讼主张的请求金额，案件尚未开庭审理，涉案金额并非法院的判决结果，最终的判决结果尚未确定。预计本 次诉讼案件不会对公司及子公司日常生产经营产生重大影响。 根据美迪西日前披露的2025年半年度报告，公司上半年实现营业收入约5.4亿元，同比增加3.64%；归母净利润亏损约1290万元，较上年同期亏损收窄 5733.19万元。净亏损收窄的原因主要系公司营收增加的同时，严格控制各项成本费用，营业成本同比减少。 图片来源：美迪西公告 涉及诉讼金额高达1.59亿元 公开资料显示，美迪西是一家专业的生物医药临床前综合研发服务CRO（医药外包）企业，其服务涵盖医药临床前新药研究的全过程，主要包括药物发 现、药学研究及临床前 ...

上海美迪西生物医药股份有限公司 关于股东权益变动触及 1%刻度的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少 | | --- | --- | --- | | 权益变动前合计比例 | 7.70% | | | 权益变动后合计比例 | 7.00% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否 | | 是否触发强制要约收购义务 | 是□ | 否 | 证券代码：688202 证券简称：美迪西 公告编号：2025-054 一致行动人名称 投资者身份 统一社会信用代码 陈国兴 □ 控股股东/实控人 □ 控股股东/实控人的一致 行动人 □ _____________ 不适用 其他直接持股股东 二、 权益变动触及 1%刻度的基本情况 公司于 2025 年 9 月 4 日收到股东林长青出具的《关于权益变动触及 1%暨减 持股份进展的告知函》。截至 2025 年 9 月 3 日，林长青已通过集中竞价和大宗交 易的方式累计减持公 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-055 上海美迪西生物医药股份有限公司 关于子公司涉及诉讼的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 案件所处的诉讼阶段：一审立案。 上市公司所处的当事人地位：上海美迪西生物医药股份有限公司（以下 简称"公司"）的全资子公司美迪西普亚医药科技（上海）有限公司（以下简称 "子公司"）为本案被告。 公司及子公司秉承"质量至上、客户至上"的原则服务客户，严格遵循 行业质量管理规范和技术要求，重视依法合规经营，就与原告鸿绪生物医药科技 （北京）有限公司（以下简称"鸿绪生物"）签订的合同，已全面、适当地履行 了合同义务，该项目已于 2023 年 12 月 14 日获批临床（受理号 CXHL2301060）。 公司及子公司对鸿绪生物的主张不予认可，将依法积极应诉，并采取包括但不限 于反诉、追究鸿绪生物相关违法行为的法律责任等措施，坚决维护公司合法权益， 切实捍卫公司及全体股东的合法权益，保障合作伙伴、服务客户及社会公众的知 情权益。 是否会对上市 ...

格隆汇9月4日丨美迪西(688202.SH)公布，公司于2025年9月4日收到股东林长青出具的《关于权益变动 触及1%暨减持股份进展的告知函》。截至2025年9月3日，林长青已通过集中竞价和大宗交易的方式累 计减持公司股份95万股，占公司总股本的0.71%。本次权益变动后，林长青持有公司股份数量由 5,473,654股减少至4,523,654股，持股比例由占公司总股本的4.07%下降至3.37%，林长青及其一致行动 人陈国兴合计持有公司股份数量由10,348,808股减少至9,398,808股，持股比例由占公司总股本的7.70% 下降至7.00%，本次权益变动触及1%的整数倍。截至本公告披露日，本次减持计划尚未实施完毕。 ...

Core Viewpoint - The CXO industry is experiencing a recovery after a period of decline, driven by increased profitability among companies and a favorable capital market environment for stock prices [1][4][10]. Group 1: Industry Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported a year-on-year increase in net profit, a significant rise from only 7 companies in the same period last year, indicating a recovery trend [1][3]. - Among the 28 stocks, 8 companies achieved a net profit increase of over 100%, with Chengdu Xian Dao leading at 390.72% [4]. - The total revenue for WuXi AppTec reached approximately 20.8 billion yuan, a year-on-year increase of 20.64%, with a net profit of about 8.56 billion yuan, up 101.92% [4]. Group 2: Market Dynamics - The recovery in the CXO industry is attributed to three main drivers: active pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biologics and complex molecules, and technological innovations such as AI in drug development [5][11]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][11]. Group 3: Company-Specific Insights - Despite the overall recovery, some companies like Tigermed reported declines in both revenue and net profit, highlighting a disparity in performance within the industry [6][8]. - Tigermed's revenue fell to approximately 3.25 billion yuan, a decrease of 3.21%, with a net profit of about 383 million yuan, down 22.22% [6][7]. - Companies with diversified client bases and technological advantages are better positioned to capitalize on market recovery, while those reliant on single business lines may face longer adjustment periods [8]. Group 4: Stock Market Performance - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanjing Momo Bio leading at a 142.21% increase [10]. - The stock price performance correlates with improved company earnings, indicating a supportive fundamental backdrop for the sector [10].

Core Viewpoint - The CXO industry is experiencing a recovery after a challenging period, with a significant increase in the number of companies reporting profit growth in the first half of the year, indicating a positive trend in the sector [1][3][4]. Financial Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported profit growth, representing approximately 57.14% of the sector [4]. - Notably, 8 companies achieved a doubling of net profit, with Chengdu Xian Dao leading at a 390.72% increase, followed by Nanmo Biology at 298.69% [4]. - Wu Ming Kang De reported the highest net profit among the companies, with approximately 8.56 billion yuan in net profit, a 101.92% year-on-year increase, and revenue of about 20.80 billion yuan, up 20.64% [4]. - Kang Long Hua Cheng, despite a 37% decline in net profit to approximately 701 million yuan, achieved a record high revenue of 6.44 billion yuan, a 14.93% increase [4][5]. Market Dynamics - The recovery in the CXO industry is driven by three main factors: increased activity in pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biopharmaceuticals and complex molecules, and technological innovations such as AI in drug development [5][6]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][6]. Performance Disparities - Despite the overall recovery, some companies like Tai Ge Yi Yao and Yi Nuo Si reported declines in both revenue and net profit, indicating uneven recovery across the sector [6][8]. - Tai Ge Yi Yao's revenue fell by 3.21% to approximately 3.25 billion yuan, with a net profit decline of 22.22% to about 383 million yuan, primarily due to decreased income from clinical trial services [6][7]. Stock Market Trends - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanmo Biology achieving the highest increase of 142.21% [10]. - The positive stock performance is supported by improved financial results and a favorable global investment environment in pharmaceuticals [10][11]. Future Outlook - The CXO industry is expected to continue its growth trajectory, driven by an aging global population and increasing health demands, although only companies with core competitive advantages will thrive [11][12].

Group 1 - Kangchen Pharmaceutical and Puris reached the daily limit increase, while Duri Pharmaceutical rose over 10% [1] - Huahai Pharmaceutical, Haoyuan Pharmaceutical, Jimin Health, Warner Pharmaceuticals, and Medisyn also experienced gains [1]

Core Insights - Meidi Xi (688202) reported a total revenue of 540 million yuan for the first half of 2025, representing a year-on-year increase of 3.64% [1] - The company achieved a net profit attributable to shareholders of -12.89 million yuan, an improvement of 81.63% compared to the previous year [1] - The gross margin increased significantly by 157.55% to 21.24%, while the net margin improved by 82.28% to -2.39% [1] Financial Performance - Total revenue for Q2 2025 was 273 million yuan, up 4.35% year-on-year [1] - Q2 net profit attributable to shareholders was 1.65 million yuan, a substantial increase of 105.05% [1] - The company reported a total of 97.42 million yuan in selling, administrative, and financial expenses, accounting for 18.03% of revenue, which is a 6.71% increase year-on-year [1] Cash Flow and Assets - Operating cash flow per share reached 0.55 yuan, a remarkable increase of 257.11% year-on-year [1] - The company's net asset per share decreased by 13.63% to 15.48 yuan [1] - The accounts receivable decreased by 15.50% to 540 million yuan, while interest-bearing debt increased by 87.89% to 431 million yuan [1] Business Development - The company has established a research and development office in Boston, covering approximately 2,000 square meters, to enhance its overseas business capabilities [4] - International clients accounted for approximately 38% of the company's main business revenue in 2024, with new overseas orders increasing by over 20% year-on-year [4] - The company aims to increase its overseas business share to 40-50% in the future, focusing on expanding its market presence and customer service capabilities [4]